References
- Liberman UA, Weiss SR, Broll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis, The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 1995; 333:1437-43
- Black DM, Cummings SR, Karpf D, et al. Randomised trial effects of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trail Research Group. Lancet 1996;348:1535-41
- Bone HG, Hosking D, Devogelaer JP, et al. Ten years’ experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004;350:1189-99
- Lufkin EG, Argueta R, Whitaker MD, et al. Pamidronate: an unrecognized problem in gastrointestinal tolerability. Osteoporosis Int 1994;4:320-2
- deGroen PC, Lubbe DF, Hirsch LJ, et al. Esophagitis associated with the use of alendronate. N Engl J Med 1996;335:1016-21
- Kikendall JW, Friedman AC, Oyewole MA, et al. Pill-induced esophageal injury: case reports and review of the medical literature. Dig Dis Sci 1983;28:174-82
- Kikendall J. Pill-induced esophageal injury. Gastroenterol Clin North Am 1991;20:835-46
- Spiller R. 1986. Where do all the tablets go? Gut 1986; 27:879-85
- Perkins AC, Wilson CG, Frier M, et al. Esophageal transit of risedronate cellulose-coated tablet and gelatin capsule formulations. Int J Pharm 1999;186:169-75
- Ferriolli E, Dantas RO, Oliveira RB, et al. The influence of ageing on oesophageal motility after ingestion of liquids with different viscosities. Eur J Gatoenterol Hepatol 1996; 8:793-8
- United States Pharmacopeia. Alendronate Sodium and Alendronic Acid Tablets, 30th edn, United States Pharmacopeial Convention, Inc., 12601 Twinbrook Parkway, Rockville, MD 20852, USA, 2007:1318-19
- Dansereau R, Crail D, Perkins AC. In vitro disintegration and dissolution studies of once-weekly copies of alendronate sodium tablets (70 mg) and in vivo implications. Curr Med Res Opin 2008;24:1137-45
- United States Pharmacopeia. Disintegration, 30th edn, United States Pharmacopeial Convention, Inc., 12601 Twinbrook Parkway, Rockville, MD 20852, USA, 2007:276-7
- European Pharmacopoeia. General Notices, 5th edn, Vol. 1, 2005;627
- Guidance for Industry, Orally Disintegrating Tablets. FDA Center for Drug Evaluation and Research (CDER), April 2007. Available at: www.fda.gov/cder/guidance/5909dft.htm [Last accessed 20 June 2008]
- Fosamax® (alendroante sodium) tablet and oral solution. Merck & Co. Inc., Whitehouse Station, NJ. Available at: www.merck.com/product/usa/pi_circulars/f/products_f.html [Last accessed 20 June 2008]